ANI director sells 6,000 shares in open market

ANI Pharmaceuticals director Patrick D. Walsh reported an open-market sale of 6,000 shares of common stock at $74.23 per share on March 3, 2026.

Rhea-AI Filing Summary

ANI Pharmaceuticals director Patrick D. Walsh reported an open-market sale of 6,000 shares of common stock at $74.23 per share on March 3, 2026. After this transaction, he directly holds 52,405 shares.

Insights

Equity ownership analyst

ANI director reports a modest open-market share sale.

Director Patrick D. Walsh sold 6,000 shares of ANI Pharmaceuticals common stock in an open-market transaction at $74.23 per share. Following the sale, his reported direct holdings stand at 52,405 shares, indicating he still retains a meaningful stake.

This is a straightforward insider sale with no accompanying narrative about intent or company developments. Subsequent company filings may provide additional context on overall insider ownership trends and whether similar transactions occur around the same period.

Insider Trade Summary

Net Seller: 6,000 shares

Net Sell 1 txn

Insider Walsh Patrick D

Role Director

Sold 6,000 shs ($445K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,000	$74.23	$445K

Holdings After Transaction: Common Stock — 52,405 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Patrick D. Walsh?

ANI Pharmaceuticals director Patrick D. Walsh reported an open-market sale of 6,000 common shares. The transaction was recorded at a price of $74.23 per share, reflecting a routine Form 4 insider trading disclosure for equity held directly by the director.

At what price were the ANI Pharmaceuticals (ANIP) shares sold in this Form 4 filing?

The reported shares were sold at $74.23 per share. This price applies to the 6,000 shares of ANI Pharmaceuticals common stock disclosed as an open-market sale, as reported in director Patrick D. Walsh’s Form 4 insider transaction filing.

How many ANI Pharmaceuticals (ANIP) shares does Patrick D. Walsh hold after the sale?

After selling 6,000 shares, Patrick D. Walsh directly holds 52,405 shares of ANI Pharmaceuticals common stock. This post-transaction balance reflects his remaining direct ownership as disclosed in the Form 4 insider trading report.

Is the Patrick D. Walsh transaction in ANI Pharmaceuticals (ANIP) a buy or a sell?

The transaction is a sale of ANI Pharmaceuticals shares. Form 4 data classify it as an open-market sale of 6,000 common shares, coded as “S,” indicating a selling transaction rather than a purchase or grant.

What type of security was involved in Patrick D. Walsh’s ANI Pharmaceuticals (ANIP) transaction?

The transaction involved ANI Pharmaceuticals Common Stock. Director Patrick D. Walsh sold 6,000 shares of this common equity security in an open-market transaction, as detailed in the Form 4 insider trading disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Patrick D

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S		6,000	D	$74.23	52,405	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Patrick D. Walsh, by attorney-in-fact Meredith W. Cook	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.